Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

NCT01294761 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

59

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Raltegravir, Darunavir/r

Sponsor

National Center for Global Health and Medicine, Japan

Collaborators

[object Object]